GlassScriptPhysician profile
Deogenes G De Leon
NPI 1598744039
$7,645.90
in general payments reported to CMS, 2019-2025
22 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,506 · 2020: $41.50 · 2021: $232 · 2022: $210 · 2023: $1,003 · 2024: $237 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608 · Education: $48.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.52 |
| Education | $48.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,456.22 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $469.90 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $326.16 | 2023-2025 | Fasenra, Tezspire, Bevespi Aerosphere |
| E.R. Squibb & Sons, L.L.C. | $295.93 | 2019-2023 | Eliquis |
| Insmed, INC. | $202.24 | 2024-2025 | Brinsupri, Arikayce |
| Jazz Pharmaceuticals INC. | $164.60 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.23 | 2023 | Glassia |
| Regeneron Healthcare Solutions, INC. | $91.62 | 2023-2024 | Dupixent |
| Grifols USA, LLC | $70.09 | 2023 | Prolastin-C Liquid |
| Genzyme Corporation | $66.41 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $60.32 | 2023 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $55.59 | 2023-2024 | Belsomra, Winrevair |
| Electromed, INC. | $44.94 | 2023 | Smartvest |
| Axsome Therapeutics, INC. | $32.01 | 2023-2024 | Sunosi |
| Mallinckrodt Hospital Products INC. | $30.57 | 2023 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $29.88 | 2019 | |
| Mylan Specialty L.P. | $24.73 | 2023 | Yupelri |
| Viatris Specialty LLC | $24.37 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $24.36 | 2019 | |
| United Therapeutics Corporation | $21.57 | 2023 | Tyvaso |
| Sunovion Pharmaceuticals INC. | $13.09 | 2019 | |
| Pulmonx Corporation | $13.07 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deogenes De Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.